**Express Mail No.: EL 500 576 1** 

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

Application of: Korngold and Huang

SEP 3 0 2002

Application No.: 09/206,786

Group Art Unit: 1644

TECH CENTER 1600/2900

Filed: December 7, 1998

Examiner: A. DeCloux

For:

CD-4 DERIVED PEPTIDES THAT

Attorney Docket No.: 8666-007

INHIBIT IMMUNE RESPONSES

Confirmation No.: 5960\_\_\_\_

## REPLY TO NOTICE TO COMPLY WITH AMENDMENT

**Assistant Commissioner for Patents** Washington, D.C. 20231

Sir:

In response to the Communication, and its enclosed Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures ("Notice to Comply"), mailed July 29, 2002, please enter the following amendments and consider the remarks below in connection with the above-identified patent application. Attached hereto as Exhibit A is a marked-up version of the amended specification indicating the amendments made herein. Also submitted herewith is (i) a Petition for an Extension of Time for Response for one month, from August 29, 2002 to and including September 29, 2002, accompanied by the appropriate fee; and (ii) a copy of the Notice to Comply.

## IN THE SPECIFICATION

Please amend the following paragraphs to recite as follows:

Amend the paragraph beginning on page 12, line 1 to recite as follows:

In the peptides of the invention, the amino acids corresponding to CD4 amino

acid residues 317-323 (SEQ ID NO:5) may be substituted as follows:

Amend the paragraph beginning on page 13, line 4 to recite as follows:

In the peptides of the invention, the amino acids corresponding to CD4 amino acid residues 346-353 (SEQ ID NO:6) max be substituted as follows: